British PBM, Harvard Pilgrim, announced this week two outcome based contracts with pharmaceutical leader AstraZeneca. The first contract will monitor the outcomes of Brilinta, a treatment lowering the chance of another heart attack or death from a heart attack in patients with coronary complications over three years. The second will monitor Bydureon, a drug which controls blood glucose levels in patients with type 2 diabetes. AstraZeneca is the latest pharmaceutical giant to form a partnership with the UK-based PBM. Read the full press release here.

Share This